NZ737592B2 - Antisense oligonucleotides to treat dystrophic epidermolysis bullosa - Google Patents
Antisense oligonucleotides to treat dystrophic epidermolysis bullosa Download PDFInfo
- Publication number
- NZ737592B2 NZ737592B2 NZ737592A NZ73759216A NZ737592B2 NZ 737592 B2 NZ737592 B2 NZ 737592B2 NZ 737592 A NZ737592 A NZ 737592A NZ 73759216 A NZ73759216 A NZ 73759216A NZ 737592 B2 NZ737592 B2 NZ 737592B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- exon
- aon
- mrna
- oligonucleotide
- aons
- Prior art date
Links
- 229920000272 Oligonucleotide Polymers 0.000 title claims abstract description 295
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title claims abstract description 211
- 239000000074 antisense oligonucleotide Substances 0.000 title claims abstract description 211
- 208000004298 Epidermolysis Bullosa Dystrophica Diseases 0.000 title claims description 27
- 108020004999 Messenger RNA Proteins 0.000 claims abstract description 84
- 229920002106 messenger RNA Polymers 0.000 claims abstract description 84
- 102100007696 COL7A1 Human genes 0.000 claims abstract description 61
- 101710040693 COL7A1 Proteins 0.000 claims abstract description 61
- 125000003729 nucleotide group Chemical group 0.000 claims description 76
- 239000002773 nucleotide Substances 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 37
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 29
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 28
- 235000000346 sugar Nutrition 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 12
- -1 excipient Substances 0.000 claims description 12
- 238000001890 transfection Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 229920001383 5S-rRNA precursor Polymers 0.000 claims description 2
- 210000004027 cells Anatomy 0.000 description 75
- 230000000295 complement Effects 0.000 description 45
- 229920002459 Intron Polymers 0.000 description 44
- 201000010099 disease Diseases 0.000 description 25
- 230000003612 virological Effects 0.000 description 19
- 229920001436 collagen Polymers 0.000 description 17
- 238000011144 upstream manufacturing Methods 0.000 description 17
- 108010035532 Collagen Proteins 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 16
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 229960005188 collagen Drugs 0.000 description 15
- 230000035772 mutation Effects 0.000 description 13
- 102000004040 Capsid Proteins Human genes 0.000 description 12
- 108090000565 Capsid Proteins Proteins 0.000 description 12
- 210000003491 Skin Anatomy 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 12
- 210000004962 mammalian cells Anatomy 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 10
- 230000001965 increased Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000006011 modification reaction Methods 0.000 description 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 10
- 210000004207 Dermis Anatomy 0.000 description 9
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 210000001519 tissues Anatomy 0.000 description 9
- 230000000692 anti-sense Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 8
- 210000000234 Capsid Anatomy 0.000 description 7
- 229920002224 Peptide nucleic acid Polymers 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 210000000056 organs Anatomy 0.000 description 7
- 210000002615 Epidermis Anatomy 0.000 description 6
- 108020004391 Introns Proteins 0.000 description 6
- 102100012486 JUN Human genes 0.000 description 6
- 210000002510 Keratinocytes Anatomy 0.000 description 6
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- ASJSAQIRZKANQN-CRCLSJGQSA-N Deoxyribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 5
- 229920000665 Exon Polymers 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 230000002452 interceptive Effects 0.000 description 5
- 238000002032 lab-on-a-chip Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 102100008005 GPR180 Human genes 0.000 description 4
- 101710028548 GPR180 Proteins 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 229920001776 Mature messenger RNA Polymers 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- 241000432074 Adeno-associated virus Species 0.000 description 3
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 229920001405 Coding region Polymers 0.000 description 3
- 102000004510 Collagen Type VII Human genes 0.000 description 3
- 108010017377 Collagen Type VII Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102100002692 NFKB1 Human genes 0.000 description 3
- 101700080605 NUC1 Proteins 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 230000004570 RNA-binding Effects 0.000 description 3
- 108020004459 Small Interfering RNA Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000038129 antigens Human genes 0.000 description 3
- 108091007172 antigens Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 101700006494 nucA Proteins 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutic aid Substances 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 239000002924 silencing RNA Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 2
- 210000002469 Basement Membrane Anatomy 0.000 description 2
- 208000002352 Blister Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710003775 ERVK-10 Proteins 0.000 description 2
- 101710037030 ERVK-11 Proteins 0.000 description 2
- 101710009283 ERVK-18 Proteins 0.000 description 2
- 101710009286 ERVK-19 Proteins 0.000 description 2
- 102000033147 ERVK-25 Human genes 0.000 description 2
- 101710035700 ERVK-25 Proteins 0.000 description 2
- 101710038044 ERVK-6 Proteins 0.000 description 2
- 101710014468 ERVK-7 Proteins 0.000 description 2
- 101710014482 ERVK-8 Proteins 0.000 description 2
- 101710043924 HERVK_113 Proteins 0.000 description 2
- 108020004996 Heterogeneous Nuclear RNA Proteins 0.000 description 2
- 201000004290 Kindler syndrome Diseases 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 210000004400 Mucous Membrane Anatomy 0.000 description 2
- 210000000282 Nails Anatomy 0.000 description 2
- 208000000837 Poikiloderma of Kindler Diseases 0.000 description 2
- 101710006375 RNASEH1 Proteins 0.000 description 2
- 101700078434 RT67 Proteins 0.000 description 2
- 102100017875 S100A8 Human genes 0.000 description 2
- 101710023380 S100A8 Proteins 0.000 description 2
- 210000004927 Skin cells Anatomy 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ANCLJVISBRWUTR-UHFFFAOYSA-M diaminophosphinate Chemical compound NP(N)([O-])=O ANCLJVISBRWUTR-UHFFFAOYSA-M 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 230000001177 retroviral Effects 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 101700086982 rnh Proteins 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 238000010153 Šidák test Methods 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- LDGWQMRUWMSZIU-UHFFFAOYSA-M 2,3-bis(octadec-9-enoxy)propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCC=CCCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCCC=CCCCCCCCC LDGWQMRUWMSZIU-UHFFFAOYSA-M 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- BEXLXSRWUSGOOV-UHFFFAOYSA-M 2-cyanohept-2-enoate Chemical compound CCCCC=C(C#N)C([O-])=O BEXLXSRWUSGOOV-UHFFFAOYSA-M 0.000 description 1
- DTKRZQKKJQWYSP-UHFFFAOYSA-M 2-cyanonon-2-enoate Chemical compound CCCCCCC=C(C#N)C([O-])=O DTKRZQKKJQWYSP-UHFFFAOYSA-M 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 1
- 102100000583 ACER3 Human genes 0.000 description 1
- 101700023946 ACER3 Proteins 0.000 description 1
- 101710016959 ALPG Proteins 0.000 description 1
- 101700053893 ATAT1 Proteins 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 108010003596 Antennapedia Homeodomain Protein Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100010924 CLEC7A Human genes 0.000 description 1
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000019679 Cell-Penetrating Peptides Human genes 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N Cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 210000004507 Chromosomes, Artificial Anatomy 0.000 description 1
- 208000001590 Congenital Abnormality Diseases 0.000 description 1
- 229920001014 CpG site Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 229940104302 Cytosine Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 102100013885 DDX58 Human genes 0.000 description 1
- 101700064525 DDX58 Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 210000001513 Elbow Anatomy 0.000 description 1
- 210000001163 Endosomes Anatomy 0.000 description 1
- 208000007217 Esophageal Stenosis Diseases 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 description 1
- 229940029575 Guanosine Drugs 0.000 description 1
- 102100016995 HNF1A Human genes 0.000 description 1
- 101700018864 HNF1A Proteins 0.000 description 1
- 210000004247 Hand Anatomy 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 210000003127 Knee Anatomy 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 210000003712 Lysosomes Anatomy 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
- 208000008198 Microstomia Diseases 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 102100020402 NOD1 Human genes 0.000 description 1
- 101700059839 NOD1 Proteins 0.000 description 1
- 102100020401 NOD2 Human genes 0.000 description 1
- 101700040223 NOD2 Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 206010030194 Oesophageal stenosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101700007624 PLB Proteins 0.000 description 1
- 108060006601 PRM1 Proteins 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229940076788 Pyruvate Drugs 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 101700074842 TAT Proteins 0.000 description 1
- 102100006352 TLR5 Human genes 0.000 description 1
- 101700025666 TLR5 Proteins 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- 210000003371 Toes Anatomy 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N Transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 229940045145 Uridine Drugs 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000010415 colloidal nanoparticle Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950010048 enbucrilate Drugs 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- SEISMQVOJUJKGE-UHFFFAOYSA-M ethyl 1,6-dimethyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-1-ium-3-carboxylate;methyl sulfate Chemical compound COS([O-])(=O)=O.C1CCC(C)N2C(=O)C(C(=O)OCC)=C[N+](C)=C21 SEISMQVOJUJKGE-UHFFFAOYSA-M 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 102000034387 fluorescent proteins Human genes 0.000 description 1
- 108091006031 fluorescent proteins Proteins 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 101710030127 hnf1a-a Proteins 0.000 description 1
- 101710030123 hnf1a-b Proteins 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 108010057670 laminin 1 Proteins 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001868 lysosomic Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
- 125000004437 phosphorous atoms Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005630 polypropylene random copolymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 201000000744 recessive dystrophic epidermolysis bullosa Diseases 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003290 ribose derivatives Chemical class 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
- 101700019592 sep-1 Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 102000002689 toll-like receptors Human genes 0.000 description 1
- 108020000411 toll-like receptors Proteins 0.000 description 1
- 230000002463 transducing Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
antisense oligonucleotide capable of preventing or reducing exon 80 inclusion into a human COL7A1 mRNA, and methods for preventing or reducing exon 80 inclusion into a human COL7A1 mRNA.
Description
(12) Granted patent specificaon (19) NZ (11) 737592 (13) B2
(47) Publicaon date: 2021.12.24
(54) ANTISENSE OLIGONUCLEOTIDES TO TREAT DYSTROPHIC EPIDERMOLYSIS BULLOSA
(51) Internaonal Patent Classificaon(s):
C12N 15/113 A61P 17/00 A61K 31/7088
(22) Filing date: (73) Owner(s):
2016.05.20 Wings Therapeutics, Inc.
(23) Complete specificaon filing date: (74) Contact:
2016.05.20 Jones Tulloch
(30) Internaonal Priority Data: (72) Inventor(s):
GB 1508733.1 2015.05.21 HAISMA, Elisabeth, Marlene
GB 1516505.3 2015.09.17 POTMAN, Marko
PLATENBURG, Gerardus, Johannes
(86) Internaonal Applicaon No.:
(87) Internaonal Publicaon number:
WO/2016/185041
(57) Abstract:
An ansense oligonucleode capable of prevenng or reducing exon 80 inclusion into a human
COL7A1 mRNA, and methods for prevenng or reducing exon 80 inclusion into a human COL7A1
mRNA.
NZ 737592 B2
ANTISENSE OLIGONUCLEOTIDES TO TREAT DYSTROPHIC EPIDERMOLYSIS BULLOSA
FIELD OF THE INVENTION
The present invention is concerned with oligonucleotides suitable for use in treating human disease.
More in particular the present invention is concerned with antisense oligonucleotides (AONs) suitable
for the treatment of dystrophic epidermolysis bullosa.
DISEASE BACKGROUND
Epidermolysis Bullosa (EB) is a group of heritable skin diseases, which are characterized by chronic
fragility and blistering of the skin and mucous membranes. Depending on the subtype, the spectrum of
symptoms of the EB is very broad, ranging from minimal skin fragility to very severe symptoms with
general complications. Worldwide about 350,000 patients are affected. In some forms of EB, also nails,
hair and teeth may be involved. The main types of EB include EB Simplex (EBS), Junctional EB (JEB),
Dystrophic EB (DEB) and Kindler syndrome (KS) (Fine et al. 2014).
DEB affects about 25% of EB patients, can be either dominantly or recessively inherited, and involves
defects in Type VII collagen (COL7A1, OMIM 120120). COL7A1 encodes the alpha-1 chain of collagen VII.
Collagen VII functions as an anchoring fibril of the upper part of the dermis to the lamina densa (part of
the basement membrane). Following post-translational modification three identical alpha-1 chains fold
together with their collagenous triple helix domain. Subsequently, antiparallel dimers are formed that
align to form the anchoring fibrils. Collagen VII is synthesized in the skin by keratinocytes and dermal
fibroblasts. DEB disease severity roughly correlates with the amount of type VII collagen expression at
the basement membrane zone.
Characteristics of Dominant Dystrophic EB (DDEB) include blistering that may be localized to the hands,
feet, elbows and knees or generalized. Common findings include scarring, milia, mucous membrane
involvement, and abnormal or absent nails. Recessive Dystrophic EB (RDEB, approximately 50% of DEB
patients) is typically more generalized and severe than DDEB. In addition to the symptoms of DDEB,
other common manifestations of RDEB include malnutrition, anemia, osteoporosis, esophageal
strictures, growth retardation, webbing, or fusion of the fingers and toes causing mitten deformity
(pseudosyndactyly), development of muscle contractures, malformation of teeth, microstomia and
scarring of the eye. The risk of squamous cell carcinoma is greatly increased in this group as well as
death from metastatic squamous cell carcinoma.
Within the gene COL7A1 more than 400 different mutations are known. One of the most prevalent
affected exons (7% of RDEB) is exon 80 with more than 3 different mutations, missense mutations or
mutations leading to premature termination codons (PTCs). Due to the fact that the majority of the
exons of the COL7A1 gene are in frame, exon skipping is potentially a viable strategy to get rid of exons
with PTC mutations, while retaining protein function (Goto et al. 2006).
Currently there is no treatment for DEB, and only palliative care is performed. Severe forms of RDEB
impose a high cost on society’s healthcare budget: the average costs of dressings and medication is
about €200,000 per patient per year. The expected life span for DEB patients is somewhere between 30
and 40 years.
WO2013/053819 of Institut National de la Santé et de la Recherche Médicale (INSERM) discloses two
40 24mer antisense oligonucleotides with 22 nucleotides that are complementary to exon 80 and 2
nucleotides that are complementary to the upstream intron, which cause the entire exon to be skipped
from the mRNA (see also Figure 1):
ESE80.3 GGCC UCUU GGAC CCUG CAGA CCCU (SEQ ID NO: 2)
ESE80.3-Q2I70X GGCC UCUU GGAC CCUA CAGA CCCU (SEQ ID NO: 3)
The exondeficient mRNA most probably translates into a functional polypeptide that, although being
shorter than the wild-type protein, behaves similarly to wild-type collagen VII. The inventors of the
present invention tested the oligonucleotides disclosed in WO2013/053819 in human primary
fibroblasts (HPF) and HeLa cells, to assess their skipping efficiency. It appears that both AONs, under the
conditions tested, exhibit a skipping efficiency of less than 50%, while ESE80.3 performs slightly better
than ESE80.3-Q2170X. Although these exon skipping oligonucleotides provide a promising first step in
tackling this terrible disease, there is clearly still a need for further alternative oligonucleotides to
improve the efficiency of exon 80 skipping.
SUMMARY OF THE INVENTION
The invention provides various AONs which are capable of preventing or reducing exon 80 inclusion into
a human COL7A1 mRNA, when said mRNA is produced by splicing from a pre-mRNA in a mammalian cell
(such as in a human cell in vivo). In a first aspect, the oligonucleotide (a) comprises a nucleotide
sequence which is complementary to part of exon 80 and (b) is less than 24 nucleotides in length. These
oligonucleotides are thus advantageously shorter than those disclosed in the prior art.
In a second aspect, the oligonucleotide comprises a nucleotide sequence which is complementary to a 3'
part of exon 80 and a 5' part of the downstream intron. AONs which span the boundary between exon
80 and its downstream intron have not previously been described, but they are shown herein to be
effective at facilitating exon skipping. For instance, these AONs can include 5'-UCACCACU-3', 5'-
ACCACUGG-3', and/or 5'-ACUCACCA-3'.
In a third aspect, the oligonucleotide does not hybridize to the intron which is upstream of exon 80. For
example, the oligonucleotide may be complementary to (part of) exon 80 but not to its upstream intron
i.e. hybridization would occur only within the downstream intron. Similarly, the oligonucleotide can
comprise a region of complementarity with (part of) exon 80, but the complementarity does not extend
into the upstream intron (and, in some embodiments, it does not even extend into either intron which
flanks exon 80). Thus, when aligned with exon 80 according to base-pairing (e.g. as shown in Figure 1)
the oligonucleotide will not include any base-pairs with the upstream intron (and, in some
embodiments, with neither the upstream nor the downstream intron). In contrast, AONs of the prior art
span exon 80 and its upstream intron (see the ‘ESE’ oligonucleotides in Figure 1).
In a fourth aspect, the oligonucleotide comprises a region of complementarity with exon 80 that is at
most 20 nucleotides in length (e.g. at most 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides; such as
at most 11-17). In contrast, the known AONs of the art include a 22mer sequence within the exon.
Oligonucleotides with 11-14 nucleotides complementary with exon 80 are shown herein to be very
effective.
Thus an antisense oligonucleotide of the invention can comprise a (a) region of complementarity with
exon 80 that is at most 20 nucleotides in length, such as 11-17 nucleotides in length, and (b) a region
40 that is complementary to the RNA transcript in an intron upstream or downstream of exon 80
(preferably in the downstream intron).
AONs of the invention are advantageously no more than 24 nucleotides long e.g. between 20-23
nucleotides long. AONs of the invention are preferably RNA AONs. Compared with natural nucleic acids
they may have chemically modified internucleosidic linkages (e.g. phosphorothioate-linkages) and they
may have modified sugars (e.g. with 2'-O-alkyl substitutions).
In a preferred embodiment, the present invention provides an antisense oligonucleotide (AON) capable
of preventing or reducing exon 80 inclusion into a human COL7A1 mRNA, when said mRNA is produced
by splicing from a pre-mRNA in a cell, wherein the AON comprises a nucleotide sequence selected from
the group consisting of SEQ ID Nos: 8, 25, 26, 31 and 32.
In a more preferred embodiment, the present invention provides an antisense oligonucleotide (AON)
capable of preventing or reducing exon 80 inclusion into a human COL7A1 mRNA when said mRNA is
produced by splicing from a pre-mRNA in a cell, wherein the AON consists of a nucleotide sequence
selected from the group consisting of SEQ ID Nos: 8, 25, 26, 31 and 32.
AONs of the invention can be formulated into pharmaceutical compositions for use in human therapy,
and can be used in methods for preventing or reducing exon 80 inclusion into a mammalian, preferably
human COL7A1 mRNA.
DESCRIPTION OF THE FIGURES
Figure 1 shows a fragment (SEQ ID NO: 1) of the human COL7A1 gene including exon 80 (upper case in
bold; SEQ ID NO: 18) with its 5' and 3' flanking intron boundaries (lower case; SEQ ID NO: 19 upstream,
and SEQ ID NO: 20 downstream), depicting underneath the various antisense oligonucleotides (AONs)
tested herein (shown in 3' to 5' orientation). ESE80.3 and ESE80.3_Q2170X were disclosed in
WO2013/053819; the other AONs are those according to the invention. The underlined nucleotides in
the RNA transcript exon 80 represent the most frequent exon 80 mutations found in EB patients. Use of
lower and upper case is only to facilitate recognition of exon (upper case) and intron (lower case)
sequences and boundaries, and for ease of alignment of oligonucleotides with their complementary
target sequence. SEQ ID NO: 22, 23 and 24 are sequences within or partly overlapping with the different
AONs of the present invention.
Figure 2 shows lab-on-a-chip results for exon skipping on human primary fibroblasts (HPF) treated with
the AONs described herein. The full-length band and the exon 80 skipped band are indicated with
arrows. Lanes 1-16 are, from left to right: empty control; maxPei control; ESE80.3; ESE80.3_Q2I70X;
AON80.1; AON80.2; AON80.3; AON80.4; AON80.5; AON80.6; AON80.7; AON80.8; AON80.9; AON80.10;
AON80.11; and AON80.12. Upper arrow indicates full length mRNA product, the lower arrow indicates
mRNA product with exon 80 excluded.
Figure 3 shows lab-on-a-chip results for exon skipping on HeLa cells treated with AONs. The location of
the full-length band and the exon 80 skipped band are the same as in Fig. 2, as are lanes 1-16.
Figure 4 shows lab-on-a-chip results of AONs, optimized from AON80.5 and tested on HPFs. AON80.5.1,
AON80.5.2 and AON80.13 have higher splicing efficiency than AON80.5.3, AON80.5.4 and AON80.5.5.
To assess the exact sequence of all the product formed, sequence analysis was performed. Extra
products visible after analysis with the bioanalyzer (upper two arrows) are those that have intron 82
included in the mRNA (as detected with sequencing analysis). Presence of intron 82 results in the
40 presence of a stop codon, which will likely lead to degradation of the protein. FL = full length.
Figure 5 shows lab-on-a-chip results for exon skipping on HPFs treated with the optimized AONs
compared to AON80.5. The upper arrow indicates full-length mRNA and the lower arrow indicates
mRNA wherein exon 80 is excluded. Lanes 1-7 are: AON80.5, AON80.5.1, AON80.5.2, AON80.5.3,
AON80.5.7, AON80.5.8 and AON80.13.
Figure 6 shows immunogenicity (NF-κB and/or AP-1 activation) in response to the indicated treatments,
including three doses for each of AON80.5 and AON80.5.1. The y-axis shows SEAP activity (OD in
655nm
arbitrary units), indicating the fold-change relative to saline. ****P<0.0001, **P<0.01, *P<0.05.
Figure 7 shows cell viability of RAW-blue macrophages after the indicated treatments, including three
doses for each of AON80.5 and AON80.5.1. The y-axis shows resorufin levels (λ / λ ),
Ex560nm Em590nm
indicating the fold-change relative to saline. ****P<0.0001, **P<0.01, *P<0.05.
DETAILED DESCRIPTION OF THE INVENTION
Surprisingly, antisense oligonucleotides (AONs) have been obtained that have similar or better exon
skipping characteristics in the assays disclosed herein compared to those disclosed in the prior art.
These AONs of the present invention can be used as active drug substances in therapies to treat human
disease, more in particular epidermolysis bullosa (EB), still more in particular EB associated with
mutations in COL7A1 exon 80. These AONs may be used as sole active drug substance, in combination
with other AONs targeting COL7A1 exon 80 (including those disclosed herein) and/or in combination
with other active drug substances for treating EB disease. Such other drug substances may be other
AONs, for example those targeting mutations in other exons (including exons 73, 74 or 3), or non-AON
active drug substances. Combination therapy may be in the form of a single composition or multiple
compositions, administered simultaneously or consecutively.
The present invention relates to an AON capable of preventing or reducing exon 80 inclusion into a
human COL7A1 mRNA when said mRNA is produced by splicing from a pre-mRNA in a cell, characterized
in that the AON comprises a nucleotide sequence: that is complementary to at least a part of exon 80
and that is not complementary to the upstream intron of exon 80 of the COL7A1 gene; or that is
complementary to at least a part of exon 80 and is less than 24 nucleotides in length. In a preferred
embodiment, the AON according to the invention comprises a region of complementarity with exon 80
wherein said region of complementarity is at most 20 nucleotides in length, preferably 11, 12, 13, 14,
, 16 or 17 nucleotides. More preferably, said AON comprises a nucleotide sequence that is
complementary to a 3' part of exon 80 and a 5' part of the downstream intron. Even more preferably,
the AON comprises the nucleotide sequence 5'-UCACCACU-3', 5'-ACCACUGG-3', or 5'-ACUCACCA-3'.
Most preferably, the AON according to the invention comprises a nucleotide sequence selected from
the group consisting of: SEQ ID NO: 7, 8, 25, 26, 28, 31 and 32.
In another embodiment, the invention relates to an AON according to the invention that is less than 24
nucleotides in length, preferably comprising 20, 21, 22, or 23 nucleotides. Preferably, said AON
comprises a nucleotide sequence of SEQ ID NO: 4 or 5, more preferably said AON comprises the
nucleotide sequence of SEQ ID NO: 6, or wherein the AON comprises the nucleotide sequence of SEQ ID
NO: 30.
The AONs according to the invention – apart from their effectiveness – have certain advantages over
40 those disclosed in the prior art in terms of manufacturability, analytics and/or cost of goods, in the sense
that the AONs of the invention are preferably shorter than those disclosed in the prior art.
Preferred AONs of the invention are less than 24, such as 20, 21, 22 or 23 nucleotides in length. Where
an AON is complementary only to exon 80 and not to either of its flanking introns (as shown herein), it
can be any length up to the 36nt length of the whole exon (e.g. AON80.13).
The shortened mRNA, lacking the entire exon 80 as a result of treatment using AONs of the invention,
will be translated into a shorter but functional COL VII protein. In some instances, however, the use of
certain AONs of the present invention do also lead to longer transcripts being formed (e.g. sequences
from intron 82), which may lead to expression of a (non-functional and easily degradable) protein
alongside the shorter (functional) protein.
Surprisingly, AONs have been identified which are capable of preventing or reducing exon 80 inclusion
into a human COL7A1 mRNA, when said mRNA is produced by splicing from a pre-mRNA in a
mammalian cell, characterized in that said oligonucleotide’s sequence is complementary to a 3' part of
exon 80 and a 5' part of the downstream intron (for instance (partly) complementary to the 24mer 5’-
CCTGGCCCAGTGgtgagtacccaa-3’ (SEQ ID NO: 21) that has 12 exon nucleotides and 12 intron
nucleotides). Previously, no AONs have been described that cover the boundary between exon 80 and
its downstream intron. Such AONs may comprise, for example: (i) the sequence 5'-UCACCACU-3' (SEQ ID
NO: 22), thus including at least 4 nucleotides from either side of the exon/intron boundary; (ii) the
sequence 5'-ACCACUGG-3' (SEQ ID NO: 23), thus including at least 2 nucleotides from the intron side of
the boundary and at least 6 nucleotides from the exon side; and/or (iii) the sequence 5'-ACUCACCA-3'
(SEQ ID NO: 24), thus including at least 6 nucleotides from the intron side of the boundary and at least 2
nucleotides from the exon side. AON80.4, AON80.5, AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4,
AON80.5.5, AON80.5.7 and AON80.5.8, (see below) are examples of such AONs. An AON of this type
ideally includes at least 2 nucleotides from each side of the boundary (e.g. at least 4 or 6 nucleotides
from each side), but it does not need to comprise the same number of nucleotides from each side (e.g.
it may have an odd number of nucleotides, such as the AON80.5 series).
Stated differently, AONs are described for the first time that are complementary to a 3' portion of exon
80, including the 3' splice site thereof, and a 5' portion of the downstream intron, and capable of
preventing or reducing exon 80 inclusion into a human COL7A1 mRNA when said mRNA is produced by
splicing from a pre-mRNA in a mammalian cell. These AONs, while being useful as such, are considered
good candidates to be combined with other AONs capable of preventing or reducing exon 80 inclusion
into a human COL7A1 mRNA, when said mRNA is produced by splicing from a pre-mRNA in a
mammalian cell, especially with those AONs that are complementary to a different portion of exon 80,
such as an internal portion of exon 80, or a 5' portion of exon 80 and/or the 5' boundary of exon 80 and
its upstream intron. Such combinations are considered to be advantageous should it be necessary to
increase the efficiency with which exon 80 is being skipped.
In other embodiments, however, an AON of the invention may hybridize only to exon 80, thus including
no region which hybridizes to the introns which are upstream and downstream of exon 80. AON80.3 is
an example of such an AON, as is AON80.13 (see below).
In further embodiments, an AON may hybridize to exon 80, but not to its upstream intron. AON80.3,
AON80.4, AON80.5, AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4, AON80.5.5, AON80.5.7, AON80.5.8
40 and AON80.13 are examples of such AONs (wherein AON80.4, AON80.5, AON80.5.1, AON80.5.2,
AON80.5.3, AON80.5.4, AON80.5.5, AON80.5.7 and AON80.5.8 are examples of AONs that hybridize also
to the intron that is directly downstream of exon 80).
In further embodiments, an AON comprises a region of complementarity with exon 80 that is at most 20
nucleotides in length (whereas the exon-complementary regions of prior art AONs are 22 nucleotides
long). Each of AON80.1, AON80.2, AON80.3, AON80.4, and AON80.5 (see Table 1 below) are examples of
such AONs, having stretches of 10, 17, 20, 12, and 12 exon-complementary nucleotides, respectively.
The AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4, AON80.5.5, AON80.5.7 and AON80.5.8 series are
further examples (with exon overlaps of 9 to 14 nucleotides). Thus the region of complementarity with
exon 80 may be between 8 and 20 (e.g. between 10 and 20 nucleotides) long, such as between 11 and
17 nucleotides, such as 11, 12, 13, 14, 15, 16 or 17 nucleotides.
For such AONs, in addition to the exon-complementary region which is <20 nucleotides long, there may
be a region that is complementary to the intron upstream or downstream of exon 80. Such AONs thus
include a single, essentially uninterrupted, stretch of complementarity with the nascent RNA transcript,
which spans the boundary between exon 80 and one of its neighbouring introns.
Specific preferred AONs of the invention are AON80.1, AON80.2, AON80.3, AON80.4, and AON80.5 as
disclosed in Table 1 and 2 below. Further preferred AONs of the invention are AON80.5.1, AON80.5.2,
AON80.5.4, AON80.5.7, AON80.5.8 and AON80.13 as disclosed in Table 1 and 2. Highly preferred AONs
according to the present invention are AON80.2 (SEQ ID NO: 5), AON80.5 (SEQ ID NO: 8), AON80.5.1
(SEQ ID NO: 25), AON80.5.2 (SEQ ID NO: 26), AON80.5.7 (SEQ ID NO: 31), AON80.5.8 (SEQ ID NO: 32)
and AON80.13 (SEQ ID NO: 30). In another preferred embodiment, all ribose moieties are 2'-O-
methylated and substantially all internucleosidic linkages are phosphorothioates.
In all embodiments of the present invention, the terms “preventing, or at least reducing, exon inclusion”
and “exon skipping” are synonymous. In respect of COL7A1, “preventing, or at least reducing, exon
inclusion” or “exon skipping” are to be construed as the exclusion of exon 80 (SEQ ID NO: 18, or allelic
forms thereof) from the human COL7A1 mRNA (see figure 1). The term exon skipping is herein defined
as the induction within a cell of a mature mRNA that does not contain a particular exon that would be
present in the mature mRNA without exon skipping. Exon skipping is achieved by providing a cell
expressing the pre-mRNA of said mature mRNA with a molecule capable of interfering with sequences
such as, for example, the splice donor or splice acceptor sequence required for allowing the biochemical
process of splicing, or with a molecule that is capable of interfering with an exon inclusion signal
required for recognition of a stretch of nucleotides as an exon to be included in the mature mRNA; such
molecules are herein referred to as exon skipping molecules.
The term pre-mRNA refers to a non-processed or partly-processed precursor mRNA that is synthesized
from a DNA template in a cell by transcription.
The term “antisense oligonucleotide” is understood to refer to a nucleotide sequence which is
complementary to a target nucleotide sequence in a pre-mRNA molecule, hnRNA (heterogeneous
nuclear RNA) or mRNA molecule, so that it is capable of annealing with its corresponding target
sequence.
The term “complementary” as used herein includes “fully complementary” and “substantially
complementary”, meaning there will usually be a degree of complementarity between the
oligonucleotide and its corresponding target sequence of more than 80%, preferably more than 85%,
40 still more preferably more than 90%, most preferably more than 95%. For example, for an
oligonucleotide of 20 nucleotides in length with one mismatch between its sequence and its target
sequence, the degree of complementarity is 95%.
The degree of complementarity of the antisense sequence is preferably such that a molecule comprising
the antisense sequence can anneal to the target nucleotide sequence in the RNA molecule under
physiological conditions, thereby facilitating exon skipping. It is well known to a person having ordinary
skill in the art, that certain mismatches are more permissible than others, because certain mismatches
have less effect on the strength of binding, as expressed in terms of melting temperature or Tm,
between AON and target sequence, than others. Certain non-complementary basepairs may form so-
called “wobbles” that disrupt the overall binding to a lesser extent than true mismatches. The length of
the AON also plays a role in the strength of binding, longer AONs having higher melting temperatures as
a rule than shorter AONs, and the G/C content of an oligonucleotide is also a factor that determines the
strength of binding, the higher the G/C content the higher the melting temperature for any given length.
Certain chemical modifications of the nucleobases or the sugar-phosphate backbone, as contemplated
by the present invention, may also influence the strength of binding, such that the degree of
complementarity is only one factor to be taken into account when designing an oligonucleotide
according to the invention.
The presence of a CpG or multitude (two or more) of CpGs in an oligonucleotide is usually associated
with an increased immunogenicity of said oligonucleotide (Dorn and Kippenberger, 2008). This increased
immunogenicity is undesired since it may induce damage of the tissue to be treated, i.e. the skin (dermis
and/or epidermis). Thus it is preferred that an AON of the invention includes no more than 1 or 2 CpG
dinucleotide sequences (preferably only one).
The invention allows designing an oligonucleotide with acceptable RNA binding kinetics and/or
thermodynamic properties. The RNA binding kinetics and/or thermodynamic properties are at least in
part determined by the melting temperature of an oligonucleotide (Tm; calculated with the
oligonucleotide properties calculator (www.unc.edu/~cail/biotool/oligo/index.html) for single stranded
RNA using the basic Tm and the nearest neighbor models), and/or the free energy of the AON-target
exon complex (using RNA structure version 4.5). If a Tm is too high, the oligonucleotide is expected to be
less specific. An acceptable Tm and free energy depend on the sequence of the oligonucleotide, the
chemistry of the backbone (phosphodiester, phosphorothioate, phosphoramidate, peptide-nucleic acid,
etc.), the nature of the sugar moiety (ribose, deoxyribose, substituted ribose, intramolecular bridge) and
chemical modification of the nucleobase. Therefore, the range of Tm can vary widely.
The exon skipping percentage or efficiency may be calculated by determining the concentration of wild-
type band amplified, divided by the concentration of the shortened (exon 80-free) band amplified, after
a given number of PCR cycles, times 100%, for any given primer set, provided the number of cycles is
such that the amplification is still in the exponential phase. Quantification can be performed using the
Agilent 2100 Bioanalyzer in combination with DNA1000 kit.
Preferably, an AON according to the invention, which comprises a sequence that is complementary to a
nucleotide sequence as shown in SEQ ID NO: 1 is such that the complementary part is at least about
80%, more preferably at least about 90%, still more preferably at least about 95%, most preferably
about 100% complementary to the target sequence. It is thus not absolutely required that all the bases
in the region of complementarity are capable of pairing with bases in the opposing strand. For instance,
40 when designing the oligonucleotide one may want to incorporate for instance a residue that does not
base pair with the base on the complementary strand. Mismatches may, to some extent, be allowed, if
under the circumstances in the cell, the stretch of nucleotides is sufficiently capable of hybridizing to the
complementary part. In this context, “sufficiently” means that the AONs according to the invention are
capable of inducing exon skipping of exon 80. Skipping the targeted exon may conveniently be assessed
by PCR/Bioanalyzer, optionally ddPCR. The complementary regions are preferably designed such that,
when combined, they are specific for the exon in the pre-mRNA. Such specificity may be created with
various lengths of complementary regions as this depends on the actual sequences in other (pre-)mRNA
molecules in the system. The risk that the oligonucleotide also will be able to hybridize to one or more
other pre-mRNA molecules decreases with increasing size of the oligonucleotide, while the length
should not be too long to create problems with manufacturability, purification and/or analytics.
It is clear that oligonucleotides comprising mismatches in the region of complementarity but that retain
the capacity to hybridize and/or bind to the targeted region(s) in the pre-mRNA, can be used in the
present invention. However, preferably at least the complementary parts do not comprise such
mismatches as these typically have a higher efficiency and a higher specificity, than oligonucleotides
having such mismatches in one or more complementary regions. It is thought, that higher hybridization
strengths, (i.e. increasing number of interactions with the opposing strand) are favorable in increasing
the efficiency of the process of interfering with the splicing machinery of the system. Preferably, the
complementarity is from 90% to 100%. In general this allows for 1 or 2 mismatch(es) in an
oligonucleotide of 20 nucleotides.
An exon skipping molecule of the invention is preferably an (antisense) oligonucleotide, which is
complementary to an exon 80 sequence (SEQ ID NO: 18) within SEQ ID NO: 1.
Preferably, the length of the complementary part of the oligonucleotide is the same as the length of the
oligonucleotide, meaning there are no 5' or 3' ends of the oligo that do not form a basepair with the
target RNA. Thus a preferred length for an oligonucleotide of the invention is 23 nucleotides or less
e.g. 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.
Particularly good results have been obtained with AONs having a length of 20, 21 or 23 nucleotides.
Where an AON is complementary only to exon 80 and not to either of its flanking introns, it may be any
length e.g. from 12-36 nucleotides long e.g. a 20mer (e.g. AON80.3) or a 36mer (e.g. AON80.13).
An exon skipping molecule according to the invention may contain one of more DNA residues
(consequently a RNA “u” residue will be a “t” residue as DNA counterpart), or one or more RNA
residues, and/or one or more nucleotide analogues or equivalents, as will be further detailed herein
below. SEQ ID NOs: 4-15 and 25-32 are RNA sequences, but the invention also encompasses each of
these sequences in DNA form, and also chimeric DNA/RNA AONs of these sequences.
It is preferred that an exon skipping molecule of the invention comprises one or more residues that are
modified to increase nuclease resistance, and/or to increase the affinity of the antisense oligonucleotide
for the target sequence. Therefore, in a preferred embodiment, the antisense nucleotide sequence
comprises at least one nucleotide analogue or equivalent, wherein a nucleotide analogue or equivalent
is defined as a residue having a modified base, and/or a modified backbone, and/or a non-natural
internucleoside linkage, or a combination of these modifications.
In a preferred embodiment, the nucleotide analogue or equivalent comprises a modified backbone.
Examples of such backbones are provided by morpholino backbones, carbamate backbones, siloxane
backbones, sulfide, sulfoxide and sulfone backbones, formacetyl and thioformacetyl backbones,
40 methyleneformacetyl backbones, riboacetyl backbones, alkene containing backbones, sulfamate,
sulfonate and sulfonamide backbones, methyleneimino and methylenehydrazino backbones, and amide
backbones. Phosphorodiamidate morpholino oligomers are modified backbone oligonucleotides that
have previously been investigated as antisense agents. Morpholino oligonucleotides have an uncharged
backbone in which the deoxyribose sugar of DNA is replaced by a six membered ring and the
phosphodiester linkage is replaced by a phosphorodiamidate linkage. Morpholino oligonucleotides are
resistant to enzymatic degradation and appear to function as antisense agents by arresting translation
or interfering with pre-mRNA splicing rather than by activating RNase H. Morpholino oligonucleotides
have been successfully delivered to tissue culture cells by methods that physically disrupt the cell
membrane, and one study comparing several of these methods found that scrape loading was the most
efficient method of delivery; however, because the morpholino backbone is uncharged, cationic lipids
are not effective mediators of morpholino oligonucleotide uptake in cells.
According to one embodiment of the invention the linkage between the residues in a backbone do not
include a phosphorus atom, such as a linkage that is formed by short chain alkyl or cycloalkyl
internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or
more short chain heteroatomic or heterocyclic internucleoside linkages.
In accordance with this embodiment, a preferred nucleotide analogue or equivalent comprises a Peptide
Nucleic Acid (PNA), having a modified polyamide backbone (Nielsen et al. 1991). PNA-based molecules
are true mimics of DNA molecules in terms of base-pair recognition. The backbone of the PNA is
composed of N-(2-aminoethyl)-glycine units linked by peptide bonds, wherein the nucleobases are
linked to the backbone by methylene carbonyl bonds. An alternative backbone comprises a one-carbon
extended pyrrolidine PNA monomer (Govindaraju and Kumar. 2005). Since the backbone of a PNA
molecule contains no charged phosphate groups, PNA-RNA hybrids are usually more stable than RNA-
RNA or RNA-DNA hybrids, respectively (Egholm et al. 1993).
According to another embodiment of the invention, the backbone comprises a morpholino nucleotide
analog or equivalent, in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino
ring. A most preferred nucleotide analog or equivalent comprises a phosphorodiamidate morpholino
oligomer (PMO), in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring,
and the anionic phosphodiester linkage between adjacent morpholino rings is replaced by a non-ionic
phosphorodiamidate linkage.
In yet a further embodiment, a nucleotide analogue or equivalent of the invention comprises a
substitution of one of the non-bridging oxygens in the phosphodiester linkage. This modification slightly
destabilizes base-pairing but adds significant resistance to nuclease degradation. A preferred nucleotide
analogue or equivalent comprises phosphorothioate, chiral phosphorothioate, phosphorodithioate,
phosphotriester, aminoalkylphosphotriester, H-phosphonate, methyl and other alkyl phosphonate
including 3'-alkylene phosphonate, 5'-alkylene phosphonate and chiral phosphonate, phosphinate,
phosphoramidate including 3'-amino phosphoramidate and aminoalkylphosphoramidate,
thionophosphoramidate, thionoalkylphosphonate, thionoalkylphosphotriester, selenophosphate or
boranophosphate.
A further preferred nucleotide analogue or equivalent of the invention comprises one or more sugar
moieties that are mono- or disubstituted at the 2', 3' and/or 5' position such as a -OH; -F; substituted or
40 unsubstituted, linear or branched lower (C1-C10) alkyl, alkenyl, alkynyl, alkaryl, allyl, or aralkyl, that may
be interrupted by one or more heteroatoms; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-or N-alkynyl; O-,
S-, or N-allyl; O-alkyl-O-alkyl, -methoxy, -aminopropoxy; methoxyethoxy; -dimethylaminooxyethoxy; and
-dimethylaminoethoxyethoxy. The sugar moiety can be a furanose or derivative thereof, or a
deoxyfuranose or derivative thereof, preferably ribose or derivative thereof, or deoxyribose or
derivative of. A preferred derivatized sugar moiety comprises a Locked Nucleic Acid (LNA), in which the
2'-carbon atom is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar
moiety. A preferred LNA comprises 2'-O,4'-C-ethylene-bridged nucleic acid (Morita et al. 2001. Nucleic
Acid Res Supplement No. 1: 241-242). These substitutions render the nucleotide analogue or equivalent
RNase H and nuclease resistant and increase the affinity for the target RNA.
It is understood by a skilled person that it is not necessary for all internucleosidic linkages in an
antisense oligonucleotide to be modified. For example, some internucleosidic linkages may be
unmodified, whereas other internucleosidic linkages are modified. AONs comprising a backbone
consisting of one form of (modified) internucleosidic linkages, multiple forms of (modified)
internucleosidic linkages, uniformly or non-uniformly distributed along the length of the AON are all
encompassed by the present invention. In addition, any modality of backbone modification (uniform,
non-uniform, mono-form or pluriform and all permutations thereof) may be combined with any form or
of sugar or nucleoside modifications or analogues mentioned below.
An especially preferred backbone for the AONs according to the invention is a uniform (all)
phosphorothioate (PS) backbone.
In another embodiment, a nucleotide analogue or equivalent of the invention comprises one or more
base modifications or substitutions. Modified bases comprise synthetic and natural bases such as
inosine, xanthine, hypoxanthine and other -aza, deaza, -hydroxy, -halo, -thio, thiol, -alkyl, -alkenyl, -
alkynyl, thioalkyl derivatives of pyrimidine and purine bases that are or will be known in the art.
It is understood by a skilled person that it is not necessary for all positions in an antisense
oligonucleotide to be modified uniformly. In addition, more than one of the aforementioned analogues
or equivalents may be incorporated in a single antisense oligonucleotide or even at a single position
within an antisense oligonucleotide. In certain embodiments, an antisense oligonucleotide of the
invention has at least two different types of analogues or equivalents.
According to another embodiment AONs according to the invention comprise a 2’-O (preferably lower)
alkyl phosphorothioate antisense oligonucleotide, such as 2'-O-methyl modified ribose (RNA), 2’-O-
methoxyethyl modified ribose, 2'-O-ethyl modified ribose, 2'-O-propyl modified ribose, and/or
substituted derivatives of these modifications such as halogenated derivatives.
An effective and preferred antisense oligonucleotide format according to the invention comprises 2’-O-
methyl modified ribose moieties with a phosphorothioate backbone, preferably wherein substantially all
ribose moieties are 2’-O-methyl and substantially all internucleosidic linkages are phosphorothioate
linkages.
It will also be understood by a skilled person that different AONs can be combined for efficiently
skipping of exon 80 of the COL7A1 gene. A combination of two AONs may be used in a method of the
invention, such as two AONs, three different AONs, four different AONs, or five different AONs targeting
the same or different regions of exon 80 (fig. 1), as long as at least one AON is one according to the
invention.
An AON can be linked to a moiety that enhances uptake of the AON in cells, preferably skin cells.
40 Examples of such moieties are cholesterols, carbohydrates, vitamins, biotin, lipids, phospholipids, cell-
penetrating peptides including but not limited to antennapedia, TAT, transportan and positively charged
amino acids such as oligoarginine, poly-arginine, oligolysine or polylysine, antigen-binding domains such
as provided by an antibody, a Fab fragment of an antibody, or a single chain antigen binding domain
such as a camelid single domain antigen-binding domain.
An exon skipping molecule according to the invention may be a naked (gymnotic) AON or in the form of
a conjugate or expressed from a vector (vectored AON). The exon skipping molecule may be
administrated using suitable means known in the art. When the exon skipping molecule is a vectored
AON, it may for example be provided to an individual or a cell, tissue or organ of said individual in the
form of an expression vector wherein the expression vector encodes a transcript comprising said
oligonucleotide. The expression vector is preferably introduced into a cell, tissue, organ or individual via
a gene delivery vehicle, such as a viral vector. In a preferred embodiment, there is provided a viral-based
expression vector comprising an expression cassette or a transcription cassette that drives expression or
transcription of an exon skipping molecule as identified herein. Accordingly, the present invention
provides a viral vector expressing an exon skipping molecule according to the invention when placed
under conditions conducive to expression of the exon skipping molecule. A cell can be provided with an
exon skipping molecule capable of interfering with sequences essential for, or at least conducive to,
exon 80 inclusion, such that such interference prevents, or at least reduces, exon 80 inclusion into the
COL7A1 mRNA, for example by plasmid-derived AON expression or viral expression provided by
adenovirus- or adeno-associated virus-based vectors. Expression may be driven by a polymerase III
promoter, such as a U1, a U6, or a U7 RNA promoter. A preferred delivery vehicle is a viral vector such
as an adeno-associated virus vector (AAV), or a retroviral vector such as a lentivirus vector and the like.
Also, plasmids, artificial chromosomes, plasmids usable for targeted homologous recombination and
integration in the mammalian (preferably human) genome of cells may be suitably applied for delivery
of an oligonucleotide as defined herein. Preferred for the current invention are those vectors wherein
transcription is driven from Pol-III promoters, and/or wherein transcripts are in the form of fusions with
U1 or U7 transcripts, which yield good results for delivering small transcripts. It is within the skill of the
artisan to design suitable transcripts. Preferred are Pol-III driven transcripts. Preferably, in the form of a
fusion transcript with an U1 or U7 transcript. Such fusions may be generated as described in the art (e.g.
vide: Gorman L et al., 1998 or Suter D et al., 1999).
One preferred AON expression system is an adenovirus associated virus (AAV)-based vector. Single chain
and double chain AAV-based vectors have been developed that can be used for prolonged expression of
AON sequences for highly efficient skipping of COL7A1 exon 80. A preferred AAV-based vector for
instance comprises an expression cassette that is driven by a polymerase III-promoter (Pol III). A
preferred Pol III promoter is, for example, a U1, a U6, or a U7 RNA promoter. The invention therefore
also provides a viral-based vector, comprising a Pol III-promoter driven expression cassette for
expression of an AON of the invention for inducing skipping of COL7A1 exon 80. An AAV vector
according to the present invention is a recombinant AAV vector and refers to an AAV vector comprising
part of an AAV genome comprising an encoded exon skipping molecule according to the invention
encapsidated in a protein shell of capsid protein derived from an AAV serotype as depicted elsewhere
herein. Part of an AAV genome may contain the inverted terminal repeats (ITR) derived from an adeno-
40 associated virus serotype, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV8, AAV9 and others. Protein
shell comprised of capsid protein may be derived from an AAV serotype such as AAV1, 2, 3, 4, 5, 8, 9 and
others. A protein shell may also be named a capsid protein shell. AAV vector may have one or preferably
all wild type AAV genes deleted, but may still comprise functional ITR nucleic acid sequences. Functional
ITR sequences are necessary for the replication, rescue and packaging of AAV virions. The ITR sequences
45 may be wild type sequences or may have at least 80%, 85%, 90%, 95, or 100% sequence identity with
wild type sequences or may be altered by for example in insertion, mutation, deletion or substitution of
nucleotides, as long as they remain functional. In this context, functionality refers to the ability to direct
packaging of the genome into the capsid shell and then allow for expression in the host cell to be
infected or target cell. In the context of the present invention a capsid protein shell may be of a
different serotype than the AAV vector genome ITR. An AAV vector according to present the invention
may thus be composed of a capsid protein shell, i.e. the icosahedral capsid, which comprises capsid
proteins (VP1, VP2, and/or VP3) of one AAV serotype, e.g. AAV serotype 2, whereas the ITRs sequences
contained in that AAV5 vector may be any of the AAV serotypes described above, including an AAV2
vector. An “AAV2 vector” thus comprises a capsid protein shell of AAV serotype 2, while e.g. an “AAV5
vector” comprises a capsid protein shell of AAV serotype 5, whereby either may encapsidate any AAV
vector genome ITR according to the invention. Preferably, a recombinant AAV vector according to the
present invention comprises a capsid protein shell of AAV serotype 2, 5, 8 or AAV serotype 9 wherein
the AAV genome or ITRs present in said AAV vector are derived from AAV serotype 2, 5, 8 or AAV
serotype 9; such AAV vector is referred to as an AAV2/2, AAV 2/5, AAV2/8, AAV2/9, AAV5/2, AAV5/5,
AAV5/8, AAV 5/9, AAV8/2, AAV 8/5, AAV8/8, AAV8/9, AAV9/2, AAV9/5, AAV9/8, or an AAV9/9 vector,
respectively. More preferably, a recombinant AAV vector according to the present invention has tropism
for dermal and epidermal cells and comprises a capsid protein shell of AAV serotype 5 or 8. The AAV
genome or ITRs present in said vector may be derived from the same or a different serotype, such as
AAV serotype 2; such vector is referred to as an AAV 2/5 or AAV 2/8 vector. AAV with a serotype 5
capsid have tropism for dermal and epidermal cells, such as basilar and suprabasilar keratinocytes and
dermal fibroblasts. AAV vectors with a type 5 capsid display much higher transduction efficiencies
compared to AAV with a type 2 capsid (Keswani et al. 2012). Similarly, AAV with a capsid of serotype 8
show tropism towards dermal fibroblasts and (mainly) suprabasilar keratinocytes. Moreover, AAV 2/8
tend to be more efficient in transducing mammalian, preferably human dermal and epidermal cells than
AAV 2/5. However, transduction efficiency appears to depend on the timing of administration during
wound healing, AAV 2/2 showing higher transduction efficiencies than AAV 2/5 and AAV 2/8 at later
time points (Keswani et al. 2012). Hence, AAV 2/2, AAV x/5 and AAV x/8 are preferred AAV to deliver
AONs according to the invention and their choice may be determined taking into account the time of
administration and the cell types to be targeted. These details can be readily worked out a person skilled
in the art, in pre-clinical or clinical studies.
A nucleic acid molecule encoding an exon skipping molecule according to the present invention
represented by a nucleic acid sequence of choice is preferably inserted between the AAV genome or ITR
sequences as identified above, for example an expression construct comprising an expression regulatory
element operably linked to a coding sequence and a 3’ termination sequence.
“AAV helper functions” generally refers to the corresponding AAV functions required for AAV replication
and packaging supplied to the AAV vector in trans. AAV helper functions complement the AAV functions
which are missing in the AAV vector, but they lack AAV ITRs (which are provided by the AAV vector
genome). AAV helper functions include the two major ORFs of AAV, namely the rep coding region and
the cap coding region or functional substantially identical sequences thereof. Rep and Cap regions are
40 well known in the art, see e.g. Chiorini et al. (1999) or US 5,139,941, incorporated herein by reference.
The AAV helper functions can be supplied on an AAV helper construct, which may be a plasmid.
Introduction of the helper construct into the host cell can occur e.g. by transformation, transfection, or
transduction prior to or concurrently with the introduction of the AAV genome present in the AAV
vector as identified herein. The AAV helper constructs of the invention may thus be chosen such that
they produce the desired combination of serotypes for the AAV vector’s capsid protein shell on the one
hand and for the AAV genome present in said AAV vector replication and packaging on the other hand.
“AAV helper virus” provides additional functions required for AAV replication and packaging. Suitable
AAV helper viruses include adenoviruses, herpes simplex viruses (such as HSV types 1 and 2) and
vaccinia viruses. The additional functions provided by the helper virus can also be introduced into the
host cell via vectors, as described in US 6,531,456 incorporated herein by reference. Preferably, an AAV
genome as present in a recombinant AAV vector according to the present invention does not comprise
any nucleotide sequences encoding viral proteins, such as the rep (replication) or cap (capsid) genes of
AAV. An AAV genome may further comprise a marker or reporter gene, such as a gene for example
encoding an antibiotic resistance gene, a fluorescent protein (e.g. gfp) or a gene encoding a chemically,
enzymatically or otherwise detectable and/or selectable product (e.g. lacZ, aph, etc.) known in the art. A
preferred AAV vector according to the present invention is an AAV vector, preferably an AAV2/5,
AAV2/8, AAV2/9 or AAV2/2 vector, expressing an exon skipping molecule according to the present
invention comprising an antisense oligonucleotide, wherein said antisense oligonucleotide comprises or
consists of a sequence selected from the group consisting of: AON80.1, AON80.2, AON80.3, AON80.4
and AON80.5 as disclosed in Table 1 below. Improvements in means for providing an individual or a cell,
tissue, organ of said individual with an exon skipping molecule according to the invention, are
anticipated considering the progress that has already thus far been achieved. Such future improvements
may of course be incorporated to achieve the mentioned effect on restructuring of mRNA using a
method of the invention. An exon skipping molecule according to the invention can be delivered as is to
an individual, a cell, tissue or organ of said individual. When administering an exon skipping molecule
according to the invention, it is preferred that the molecule is dissolved in a solution that is compatible
with the delivery method.
Gymnotic AONs are readily taken up by most cells in vivo, and usually dissolving the AONs according to
the invention in an isotonic (saline) solution will be sufficient to reach the target cells, such as skin
(dermis and epidermis) cells. Alternatively, gymnotic AONs of the invention may be formulated using
pharmaceutically acceptable excipients, additives, stabilizers, solvents, colorants and the like. In
addition, or alternatively, gymnotic AONs may be formulated with any of the transfection aids
mentioned below.
Skin (dermis and epidermis) cells can be provided with a plasmid for antisense oligonucleotide
expression by providing the plasmid in an aqueous solution, such as an isotonic (saline) solution.
Alternatively, a plasmid can be provided by transfection using known transfection agents.
For intravenous, subcutaneous, intramuscular, intrathecal and/or intraventricular administration it is
preferred that the solution is an isotonic (saline) solution. Particularly preferred in the invention is the
use of an excipient or transfection agents that will aid in delivery of each of the constituents as defined
herein to a cell and/or into a cell, preferably a skin (dermis and epidermis) cell. Preferred are excipients
or transfection agents capable of forming complexes, nanoparticles, micelles, vesicles and/or liposomes
that deliver each constituent as defined herein, complexed or trapped in a vesicle or liposome through a
cell membrane. Many of these excipients are known in the art. Suitable excipients or transfection agents
40 comprise polyethylenimine (PEI; ExGen500 (MBI Fermentas)), LipofectAMINE™ 2000 (Invitrogen) or
derivatives thereof, or similar cationic polymers, including polypropyleneimine or polyethylenimine
copolymers (PECs) and derivatives, synthetic amphiphils (SAINT-18), lipofectin™, DOTAP and/or viral
capsid proteins that are capable of self-assembly into particles that can deliver each constitutent as
defined herein to a cell, preferably a skin (dermis r epidermis) cell. Such excipients have been shown to
efficiently deliver an oligonucleotide such as antisense nucleic acids to a wide variety of cultured cells,
including skin (dermis and epidermis) cells. Their high transfection potential is combined with an
acceptably low to moderate toxicity in terms of overall cell survival. The ease of structural modification
can be used to allow further modifications and the analysis of their further (in vivo) nucleic acid transfer
characteristics and toxicity.
Lipofectin represents an example of a liposomal transfection agent. It consists of two lipid components,
a cationic lipid N-[1-(2,3 dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) (cp. DOTAP
which is the methylsulfate salt) and a neutral lipid dioleoylphosphatidylethanolamine (DOPE). The
neutral component mediates the intracellular release. Another group of delivery systems are polymeric
nanoparticles.
Polycations such like diethylaminoethylaminoethyl (DEAE)-dextran, which are well known as DNA
transfection reagent can be combined with butylcyanoacrylate (PBCA) and hexylcyanoacrylate (PHCA) to
formulate cationic nanoparticles that can deliver each constituent as defined herein, preferably an
oligonucleotide, across cell membranes into cells.
In addition to these common nanoparticle materials, the cationic peptide protamine offers an
alternative approach to formulate an oligonucleotide with colloids. This colloidal nanoparticle system
can form so called proticles, which can be prepared by a simple self-assembly process to package and
mediate intracellular release of an oligonucleotide. The skilled person may select and adapt any of the
above or other commercially available alternative excipients and delivery systems to package and
deliver an exon skipping molecule for use in the current invention to deliver it for the prevention,
treatment or delay of a disease or condition associated with a mutated exon 80 in the COL7A1 gene.
An exon skipping molecule according to the invention could be covalently or non-covalently linked to a
targeting ligand specifically designed to facilitate the uptake into the cell (especially a skin (dermis) cell),
cytoplasm and/or its nucleus. Such ligand could comprise (i) a compound (including but not limited to
peptide(-like) structures) recognizing cell, tissue or organ specific elements facilitating cellular uptake
and/or (ii) a chemical compound able to facilitate the uptake in to cells and/or the intracellular release
of an oligonucleotide from vesicles, e.g. endosomes or lysosomes.
Therefore, in a preferred embodiment, an exon skipping molecule according to the invention is
formulated in a composition or a medicament or a composition, which is provided with at least an
excipient and/or a targeting ligand for delivery and/or a delivery device thereof to a cell and/or
enhancing its intracellular delivery.
It is to be understood that if a composition comprises an additional constituent such as an adjunct
compound as later defined herein, each constituent of the composition may be formulated in one single
combination or composition or preparation. Depending on their identity, the skilled person will know
which type of formulation is the most appropriate for each constituent as defined herein. According to
one embodiment, the invention provides a composition or a preparation which is in the form of a kit of
parts comprising an exon skipping molecule according to the invention and a further adjunct compound
as later defined herein.
If required, an exon skipping molecule according to the invention or a vector, preferably a viral vector,
expressing an exon skipping molecule according to the invention can be incorporated into a
pharmaceutically active mixture by adding a pharmaceutically acceptable carrier.
Accordingly, the invention also provides a composition, preferably a pharmaceutical composition,
comprising an exon skipping molecule according to the invention, such as gymnotic AON or a viral vector
according to the invention and a pharmaceutically acceptable excipient. Such composition may
comprise a single exon skipping molecule according to the invention, but may also comprise multiple,
distinct exon skipping molecules according to the invention. Such a pharmaceutical composition may
comprise any pharmaceutically acceptable excipient, including a carrier, excipient, stabilizer,
transfection agent, gelling agent, buffer, filler, preservative, adjuvant, solubilizer and/or diluent. Such
pharmaceutically acceptable components may for instance be found in Remington, 2000. Each feature
of said composition has earlier been defined herein.
If multiple distinct exon skipping molecules according to the invention are used, concentration or dose
defined herein may refer to the total concentration or dose of all oligonucleotides used or the
concentration or dose of each exon skipping molecule used or added. Therefore in one embodiment,
there is provided a composition wherein each or the total amount of exon skipping molecules according
to the invention used is dosed in an amount ranged from 0.0001 and 100 mg/kg, preferably from 0.001
and 50 mg/kg, still more preferably between 0.01 and 20 mg/kg.
A preferred exon skipping molecule according to the invention is for the treatment of DEB or, more
generally, a mutated COL7A1 exon 80 related disease or condition of an individual. In all embodiments
of the present invention, the term “treatment” is understood to include the prevention and/or delay of
the disease or condition. An individual, which may be treated using an exon skipping molecule according
to the invention may already have been diagnosed as having DEB or a COL7A1 exon 80 related disease
or condition. Alternatively, an individual which may be treated using an exon skipping molecule
according to the invention may not have yet been diagnosed, but may be an individual having an
increased risk of developing DEB, or a COL7A1 exon 80 related disease or condition in the future given
his or her genetic background. A preferred individual is a human being. In a preferred embodiment the
mutated COL7A1 exon 80 related disease or condition is Dystrophic Epidermolysis Bullosa (DEB).
The present invention further provides an exon skipping molecule according to the invention, such as an
AON, or a vector encoding an AON, such as a viral vector, according to the invention, or a composition
comprising an AON, or a vector encoding an AON, according to the invention for use as a medicine
e.g. for use in treating DEB or, more generally, a mutated COL7A1 exon 80 related disease or condition
of an individual (as discussed above).
The invention further provides the use of an exon skipping molecule according to the invention, such as
an AON, or a vector encoding an AON, such as a viral vector, according to the invention, or a
composition comprising an AON, or a vector encoding an AON, according to the invention in the
manufacture of a medicament for treating DEB or, more generally, a mutated COL7A1 exon 80 related
disease or condition of an individual (as discussed above).
The invention further provides a method for treating a mammal (preferably a human) carrying in its
40 genome a mutation in exon 80 of the COL7A1 gene causing a disease or disorder, including DEB,
comprising administering to the mammal (human) an AON, a (viral) vector, or a pharmaceutical
composition of the invention. These patients may suffer, or be at risk of developing DEB or a related
disorder. Related disorder, disease or condition also encompasses for example skin cancer (melanoma),
or other carcinomas, that may arise as a consequence of a collagen VII deficiency or abnormality in the
skin, or other organs of an individual, caused by or associated with a mutation in exon 80 of the COL7A1
gene.
Further embodiments of the invention are AONs, viral vectors encoding AONs, and pharmaceutical
compositions comprising AONs according to the invention for use as a medicine to treat a mammal
(preferably a human) carrying in its genome a mutation in exon 80 of the COL7A1 gene.
Exon skipping molecules according to the invention may be administered to a patient systemically,
locally, topically, through administration that is orally, intraocularly, intrapulmonary, intranasally,
intramuscularly, subcutaneously, intradermally, rectally, by swallowing, injecting, inhalation, infusion,
spraying, in the form of (aqueous) solutions, suspensions, (oil-in-water) emulsions, ointments, lozenges,
pills etcetera.
One preferred method of administration of AONs according to the invention is by the appliance of AON-
coated bandages capable of releasing the AONs. Especially beneficial are multilayered (Layer-by-Layer,
LbL)-coated bandages such as disclosed in WO2014/150074. The international patent application filed in
the name of MIT discloses prolonged and effective release of a wound-healing-promoting siRNA from an
adhesive bandage, coated with a multi-layered film containing said siRNA. A bandage that may suitably
be used in combination with AONs according to the invention, is Tegaderm®. Suitable multilayer
coatings for the delivery of siRNA that may also be used in combination with AONs according to the
invention, comprises a Laponite® containing layer-by-layer architecture. Other bandages than
Tegaderm® that are capable of releasing nucleic acid therapeutics, may be used. Also non-adhesive
bandages may be used, as they are likely to be less painful for the patient, as long as the bandage is in
close contact with the skin or the wound-site. AON-containing LBL films for delivery of AONs according
to the invention in combination with bandages are described in WO2014/150074.
Dosing may be daily, weekly, monthly, quarterly, once per year, depending on the route of
administration and the need of the patient.
Because of the early onset of disease, patients having or at risk of developing a disease, disorder or
condition caused by or associated with a mutated exon 80 of the COL7A1 gene, including DEB, may be
treated in utero, directly after birth, from 1, 2, 3, 6 months of age, from one year of age, from 3 years of
age, from 5 years of age, prior to or after the onset of symptoms, to alleviate, retard development, stop
or reverse the symptoms of disease and the like.
A treatment in a use or in a method according to the invention is at least one week, at least one month,
at least several months, at least one year, at least 2, 3, 4, 5, 6 years or chronically, even during a
patient’s entire life. Each exon skipping molecule or exon skipping oligonucleotide or equivalent thereof
as defined herein for use according to the invention may be suitable for direct administration to a cell,
tissue and/or an organ in vivo of individuals already affected or at risk of developing a mutated COL7A1
exon 80 related disorder, disease or condition, and may be administered directly in vivo, ex vivo or in
vitro. The frequency of administration of an AON, composition, compound or adjunct compound of the
invention may depend on several parameters such as the age of the patient, the nature of the exon
40 skipping molecule (e.g. gymnotic AON or vectored AON, such as AAV or lentiviral vector expressed
AONs), the dose, the formulation of said molecule and the like.
Dose ranges of an exon skipping molecule, preferably an oligonucleotide according to the invention are
preferably designed on the basis of rising dose studies in clinical trials (in vivo use) for which rigorous
protocol requirements exist. An oligonucleotide as defined herein may be used at a dose range from
0.0001 to 100 mg/kg, preferably from 0.01 to 20 mg/kg. The dose and treatment regime may vary
widely, depending on many factors, including but not limited to the route of administration (e.g.
systemic versus topically), whether the oligo is administered as a gymnotic AON or as vectored AON, the
dosing regimen, the age and weight of the patient, and so forth.
In a preferred embodiment, a viral vector, preferably an AAV vector as described earlier herein, as
delivery vehicle for a molecule according to the invention, is administered in a dose ranging from 1x10
17 10 14 10
– 1x10 virus particles per injection, more preferably from 1x10 – 1x10 , and most preferably 1x10 –
1x10 virus particles per injection.
It will be clear to a person having ordinary skill in the art to which this invention pertains, that the details
of treatment will need to be established in accordance with and depending on such factors as the
sequence and chemistry of the oligonucleotide(s), the route of administration, the formulation, the
dose, the dosing regimen, the format (viral vector or gymnotic oligonucleotide), the age and weight of
the patient, the stage of the disease and so forth, which may require further non-clinical and clinical
investigation.
The invention further provides a method for preventing, or at least reducing, COL7A1 exon 80 inclusion
in a cell comprising contacting the cell, preferably a skin (dermis) cell, with an exon skipping molecule
according to the invention, such as a gymnotic AON or a (viral) vector encoding an AON according to the
invention, or a composition according to the invention. The features of this aspect are preferably those
defined earlier herein.
Unless otherwise indicated each embodiment as described herein may be combined with another
embodiment as described herein.
The present invention relates to an antisense oligonucleotide capable of preventing or reducing exon 80
inclusion into a human COL7A1 mRNA, when said mRNA is produced by splicing from a pre-mRNA in a
mammalian cell; characterized in that the oligonucleotide (a) comprises a nucleotide sequence which is
complementary to part of exon 80 and (b) is less than 24 nucleotides in length.
In another aspect the invention relates to an antisense oligonucleotide capable of preventing or
reducing exon 80 inclusion into a human COL7A1 mRNA, when said mRNA is produced by splicing from a
pre-mRNA in a mammalian cell; characterized in that the oligonucleotide comprises a nucleotide
sequence which is complementary to a 3' part of exon 80 and a 5' part of the downstream intron.
Preferably, said oligonucleotide comprises a nucleotide sequence which is complementary to SEQ ID
NO: 21. For example, said oligonucleotide comprises SEQ ID NO: 22 (5'-UCACCACU-3'), SEQ ID NO: 23
(5'-ACCACUGG-3'), and/or SEQ ID NO: 24 (5'-ACUCACCA-3').
In another aspect the invention relates to an antisense oligonucleotide capable of preventing or
reducing exon 80 inclusion into a human COL7A1 mRNA, when said mRNA is produced by splicing from a
pre-mRNA in a mammalian cell; characterized in that the oligonucleotide comprises SEQ ID NO: 22 (5'-
UCACCACU-3'), SEQ ID NO: 23 (5'-ACCACUGG-3'), and/or SEQ ID NO: 24 (5'-ACUCACCA-3').
Preferably, an oligonucleotide according to the present invention is less than 24 nucleotides, in certain
embodiments preferably between 20 and 23 nucleotides, in length. Hence, preferably, said
oligonucleotide is 20, 21, 22 or 23 nucleotides in length.
In a preferred aspect, the oligonucleotide is selected from the group consisting of AON80.1, AON80.2,
AON80.3, AON80.5, AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4, AON80.5.5, AON80.5.7 and
AON80.5.8. Preferably, said oligonucleotide is selected from the groups consisting of:
(i) AON80.2 and AON80.5;
(ii) AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4, and AON80.5.5; or
(iii) AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4, AON80.5.5, AON80.5.7 and AON80.5.8.
In yet another preferred embodiment, the oligonucleotide is selected from the group consisting of
AON80.4, AON80.5, AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4, AON80.5.5, AON80.5.7 and
AON80.5.8.
The present invention also relates to an antisense oligonucleotide capable of preventing or reducing
exon 80 inclusion into the human COL7A1 mRNA, when said mRNA is produced by splicing from an RNA
transcript in a mammalian cell, characterized in that said antisense oligonucleotide does not hybridize to
the intron which is upstream of exon 80. Preferably, said mammalian cell is a human cell. Preferably the
sequence of said oligonucleotide comprises the sequence of an oligonucleotide of the group consisting
of AON80.3, AON80.4, AON80.5, AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4, AON80.5.5,
AON80.5.7, AON80.5.8 and AON80.13.
In another embodiment, the invention relates to an antisense oligonucleotide capable of preventing or
reducing exon 80 inclusion into the human COL7A1 mRNA, when said mRNA is produced by splicing
from an RNA transcript in a mammalian cell, characterized in that said antisense oligonucleotide is
complementary to exon 80 but not to its upstream or downstream introns. In yet another embodiment,
the invention relates to an antisense oligonucleotide capable of preventing or reducing exon 80
inclusion into a human COL7A1 mRNA, when said mRNA is produced by splicing from a pre-mRNA in a
mammalian cell; wherein the oligonucleotide comprises a region of complementarity with exon 80,
which region of complementarity does not extend into either of the introns which flanks exon 80. In
such embodiments, the oligonucleotide is preferably AON80.3 or AON80.13.
The present invention also relates to an antisense oligonucleotide capable of preventing or reducing
exon 80 inclusion into the human COL7A1 mRNA, when the mRNA is produced by splicing from an RNA
transcript in a mammalian cell, characterized in that said antisense oligonucleotide comprises a region
of complementarity with exon 80 that is at most 20 nucleotides in length. Preferably, said
oligonucleotide comprises a sequence of an oligonucleotide from the group consisting of AON80.1,
AON80.2, AON80.3, AON80.4, AON80.5, AON80.5.1, AON80.5.2, AON80.5.3, AON80.5.4, AON80.5.5,
AON80.5.7 and AON80.5.8. Preferably, said region of complementarity with exon 80 is at most between
9 and 17 nucleotides, such as 9, 10, 11, 12, 13, 14, 15, 16 or 17 nucleotides. More preferably, when the
oligonucleotide has a region of complementarity with the intron that is directly downstream of exon 80,
the region of complementarity with exon 80 is 9 to 14 nucleotides, such as 9, 10, 11, 12, 13 or 14
nucleotides. When the portion complementary to exon 80 is at most 12 nucleotides, then the
40 oligonucleotide is preferably selected from the group consisting of AON80.1, AON80.4, AON80.5,
AON80.5.3, AON80.5.4, AON80.5.5, AON80.5.7 and AON80.5.8. In another preferred aspect, the
antisense oligonucleotide comprises a (a) region of complementarity with exon 80 that is at most 20
nucleotides in length and (b) a region that is complementary to the RNA transcript in an intron upstream
or downstream of exon 80. Even more preferred, the antisense oligonucleotide comprises a portion that
is complementary with the RNA transcript in an intron downstream of exon 80. In one embodiment, the
antisense oligonucleotide comprises a portion that is complementary to a portion of exon 80 consisting
of the ten 3'-most nucleotides of SEQ ID NO: 18 (i.e. nucleotides 27-36 of SEQ ID NO: 18). In yet another
embodiment, the portion of complementarity to exon 80 consists of the n-most 3' nucleotides of SEQ ID
NO: 18, where n is between 9 and 20; such as 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 3'-most
nucleotides of SEQ ID NO: 18. In a more preferred embodiment, the portion of exon 80 consists of the
12 3'-most nucleotides of exon 80 (i.e. nucleotides 25-36 of SEQ ID NO: 18). When the oligonucleotide is
complementary to part of exon 80, its sequence has preferably a length of no more than 24 nucleotides.
Regarding all antisense oligonucleotides according to the present invention, preferably the antisense
oligonucleotide is an oligoribonucleotide, more preferably wherein the internucleosidic linkages are
chemically modified, preferably phosphorothioate-linkages. In yet another preferred aspect, the sugar
moieties of the oligonucleotide are lower 2’-O-alkyl, preferably 2’-O-methyl substituted sugar moieties.
The invention relates also to an oligonucleotide comprising or consisting of: (i) a nucleotide sequence
selected from the group consisting of SEQ ID NOs: 4-17 and 25-32; (ii) a RNA nucleotide sequence
selected from the group consisting of SEQ ID NOs: 4-15 and 25-32; or (iii) a DNA nucleotide sequence
selected from the group consisting of SEQ ID NOs: 4-15 and 25-32 in which any U is replaced by a T.
The invention also relates to a composition comprising an oligonucleotide according to the invention,
optionally comprising one or more of a carrier, excipient, stabilizer, transfection agent, diluent, gelling
agent or a buffer. Preferably said composition is a pharmaceutical composition for use in human
therapy, more preferably for use in the treatment of dystrophic epidermolysis bullosa (DEB), even more
preferably for use in the treatment of a human subject suffering from DEB that is caused by a mutation
in exon 80 of the COL7A1 gene. In another embodiment, the invention relates to an antisense
oligonucleotide according to the invention for use in the treatment of a human subject that suffers from
a disease caused by the inclusion of a mutated exon 80 in the COL7A1 gene.
The invention also relates to a method for preventing or reducing exon 80 inclusion into a mammalian,
preferably human COL7A1 mRNA, when said mRNA is produced by splicing from a RNA transcript in a
mammalian, preferably human, cell; comprising the steps of providing to a cell, to a tissue, in vitro or ex
vivo, or to a living animal, including a human being, comprising such a cell, an antisense oligonucleotide
according to any one of claims 1 to 27, or a composition according to claim 29 or claim 30, under
conditions conducive to uptake of such oligonucleotide by such cell, and allowing splicing to take place.
The ability of an exon skipping molecule, such as an AON according to the invention, or a (viral) vector
encoding such AON, to prevent, or at least reduce, mutated COL7A1 exon 80 inclusion, when the
COL7A1 gene is expressed in a mammalian (preferably human) cell, and to bind to the mammalian
(human) COL7A1 pre-mRNA under physiological conditions in a region affecting selection of the 5’ splice
acceptor, and thereby reduce inclusion of the mutated exon 80 into the COL7A1 mRNA, can be
conveniently assessed using the assays disclosed in the experimental section herein. In particular, the
exon skipping molecule can be incubated with a cell containing exon 80 (not necessarily mutated) of the
40 COL7A1 gene to assess its ability to reduce production by the cell of mRNA which includes exon 80,
e.g. by RT-PCR (which can be quantified using a Bioanalyzer apparatus), as described herein in the
experimental section and the examples.
As can be observed in the experimental section and the Examples herein, at the RNA level, addition of
various AONs according to the invention targeting exon 80 of the COL7A1 gene indeed resulted in a
mRNA lacking exon 80, leading to the production of a shorter but functional collagen VII protein.
In fibroblasts (that can be derived from skin cells), collagen VII is abundantly expressed. Therefore, it is
to be expected that addition of AONs to cultured fibroblasts from DEB patients will result in an
increased amount of shortened but functional collagen VII protein that is detectable on Western blot,
and as such will demonstrate that AON-based therapy will not only redirect splicing of the COL7A1
mRNA but will also result in restoring collagen VII functionality.
The terms “adenine”, “guanine”, “cytosine”, “thymine”, “uracil” and hypoxanthine (the nucleobase in
inosine) refer to the nucleobases as such.
The terms adenosine, guanosine, cytidine, thymidine, uridine and inosine, refer to the nucleobases
linked to the (deoxy)ribosyl sugar.
The term “nucleoside” refers to the nucleobase linked to the (deoxy)ribosyl sugar.
In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting
sense to mean that items following the word are included, but items not specifically mentioned are not
excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the
possibility that more than one of the element is present, unless the context clearly requires that there
be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".
The word “include” and all of its tenses and conjugations, is to be read as “include, but is not limited to”.
The word “exon skipping molecule” is meant to include gymnotic AONs and vectored AONs, including
viral vectors, capable of expressing AONs in a compatible cell.
The word “about” or “approximately” when used in association with a numerical value (e.g. about 10)
preferably means that the value may be the given value (of 10) plus or minus 5% of the value.
The sequence information as provided herein should not be so narrowly construed as to require
inclusion of erroneously identified bases. The skilled person is capable of identifying such erroneously
identified bases and knows how to correct for such errors. In case of sequence errors, the sequence of
the polypeptide obtainable by expression of the sequence present in SEQ ID NO: 1 containing the
nucleic acid sequence coding for the polypeptide should prevail.
EXAMPLES
Example 1: mRNA analysis of exon 80
To detect the presence of mRNA of exon 80 in mRNA of COL7A1 extracted total RNA of both HeLa cells
and primary human fibroblasts (HPF) cells were used. Culturing of cells was performed in (a) Dulbecco's
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) for HeLa, or
(b) DMEM AQE supplemented with 20% FBS and 1% natrium pyruvate for HPF cells. All cells were grown
at 37°C 5% CO . To determine the exon skipping efficiency of the AONs, cells were seeded at 60.000
cells/well (HeLa) into 12-well plates or 150.000 cells/well (LFB1) into 6-well plates. After 24 hours of
allowing cell growth cells were transfected with 100nm AON-maxPei complex. RNA isolation was
performed with the ReliaPrep™ RNA Cell Miniprep System (Promega). Subsequently cDNA was made
using the Thermo Scientific Verso kit. PCR for exon 80 was performed with FW primer (5'-
CAAGGTCCCAAAGGAGACAG-3'; SEQ ID NO: 16) located at exon 77 and a RV primer, which is either an
RV primer with sequence 5'-AGTCCCACAGCTCCAGTAGG-3' (SEQ ID NO: 17) located within exon 84, or
with an RV primer with sequence 5’-GAAGGGGGAGCCTGGAGA-3’ (SEQ ID NO: 33) located at the exon
82/83 boundary. PCR products were visualized with the Bioanalyzer using DNA1000 chips and software
Expert 2100 was used for product length analysis. Initial oligonucleotide design led to twelve
oligonucleotides, AON80.1 to AON80.12, and Table 1 shows for each of these AONs the semi-
quantitative skipping efficiency of exon 80 in human primary fibroblasts (HPF) and HeLa cells. Further
design work based on the AON80.5 21-mer led to five derivatives, named AON80.5.1 to AON80.5.5 (all
21-mers). Also, a 36-mer oligonucleotide (AON80.13) was designed over the complete exon 80. Data for
these further AONs is also included in Table 1, together with the nucleotide sequence and SEQ ID NO of
preferred AONs according to the invention (AON80.1 – AON80.5, and AON80.5.n series, and AON80.13).
Two 20-mer oligonucleotides (AON80.5.7 and AON80.5.8) were tested in 3 experiments. Results are
shown in Table 2 and show comparable results.
Table 1: Efficiency of exon 80 exclusion from mRNA. Cells were treated for 24 hours with 100nM AON.
For comparison ESE-80.3 and ESE-80.3_Q2170X from WO2013/053819 were used. Data are
represented as: - (no exon 80 exclusion), + (1-10% exon exclusion), ++ (11-20% exon 80 exclusion), +++
(21-30% exon 80 exclusion), etc.
AON HPF HeLa Sequence 5’ – 3’ SEQ ID NO
GGCCUCUUGGACCCUGCAGACCCU
ESE80.3 +++ ++++ 2
GGCCUCUUGGACCCUACAGACCCU
ESE80.3_Q2170X ++ ++++ 3
CCUGCAGACCCUACAUAGAG
AON80.1 + + 4
CUUGGACCCUGCAGACCCUA
AON80.2 ++++ ++++ 5
GGGCCUCUUGGACCCUGCAG
AON80.3 ++ ++ 6
UUGGGUACUCACCACUGGGCCAGG
AON80.4 ++ +++ 7
GGUACUCACCACUGGGCCAGG
AON80.5 +++++++ ++ 8
GUACUCACCACUGGGCCAGGG
AON80.5.1 +++++++ +++++++ 25
UACUCACCACUGGGCCAGGGG
AON80.5.2 +++++ ++++ 26
GGGUACUCACCACUGGGCCAG
AON80.5.3 - - 27
UGGGUACUCACCACUGGGCCA
AON80.5.4 ++ ++ 28
UUGGGUACUCACCACUGGGCC
AON80.5.5 - - 29
GGCAAGACAGGUGAAGGUUCUUGG
AON80.6 - - 9
AON80.7 - - CAGGGCACAGGAUGGGGGCAAGACA 10
GUCACUGGGGCAGGGCACAGGAUGG
AON80.8 - - 11
CUUGGGCCUGUUCCCAACCUCUGGG
AON80.9 - - 12
AUCUGGGCCUCACUUGGGCCUG
AON80.10 - - 13
AGGGCACUGAUGAGCCUCAAUCUGG
AON80.11 - - 14
CAUAGAGAGGGCACUGAUGAGCCUC
AON80.12 - - 15
++++++++ CACUGGGCCAGGGGGGCCUCUUGGACCCUGCAGACC
AON80.13 +++++++ 30
Table 2: Efficiency of exon 80 exclusion from mRNA. The mean results are shown for three
independent experiments performed as for Table 1, with two new AONs (AON80.5.7 and
AON80.5.8) and compared to AONs tested before (see above). Data are represented as in Table 1.
AON HPF HeLa Sequence 5’ – 3’ SEQ ID NO
GGUACUCACCACUGGGCCAGG
AON80.5 +++++++ +++++++ 8
GUACUCACCACUGGGCCAGGG
AON80.5.1 +++++++ +++++++ 25
AON80.5.2 +++++ ++++++ UACUCACCACUGGGCCAGGGG 26
GGGUACUCACCACUGGGCCAG
AON80.5.3 + - 27
UGGGUACUCACCACUGGGCCA
AON80.5.4 ++ ++ 28
UUGGGUACUCACCACUGGGCC
AON80.5.5 - - 29
GUACUCACCACUGGGCCAGG
AON80.5.7 ++++++ ++++++ 31
GGUACUCACCACUGGGCCAG
AON80.5.8 ++++++ ++++++ 32
++++++++ CACUGGGCCAGGGGGGCCUCUUGGACCCUGCAGACC
AON80.13 +++++++ 30
Figures 2-5 show lab-on-a-chip results for the Table 1 and 2 AONs. The AONs according to the invention
designated AON80.1 to AON80.5 have good efficiency, AON80.2, AON80.4 and AON80.5 performing
better. From the further design work, AON80.5.1, AON80.5.2, AON80.5.7, AON80.5.8 and AON80.13
appear to have the best splicing efficiency of the AONs tested. Most preferred AONs according to the
invention are AON80.5, AON80.5.1, AON80.5.2, AON80.5.7 and AON80.5.8.
To assess the exact sequence of all the products formed, sequence analysis was performed. Extra
products visible after analysis with the bioanalyzer included intron 82 in the mRNA (as observed with
sequencing analysis). If this intron would be translated to protein, however, a stop codon would be
included leading to a truncated collagen protein, that most likely will be degraded.
To assess the immunogenic effect of AONs the following in vitro experimental procedure can be
followed, using the RAW-Blue cells of Invivogen. These RAW-Blue cells are derived from the murine
RAW 264.7 macrophages and have an integrated secreted embryonic alkaline phosphatase (SEAP)
reporter construct inducible by NF-κB and AP-1. The presence of agonists of all TLRs (with the exception
of TLR5), NOD1, NOD2, RIG-I, MDA or DECTIN-1 induces signaling pathways leading to the activation of
NF-κB and AP-1 and the subsequent production of SEAP. Levels of SEAP can be detected, thus indicating
immunogenic activation. Figure 6 shows the results of such testing after 24hrs of in vitro stimulation.
Positive controls CpG-DNA, LPS and R848 activated NF-κB and/or AP-1. In contrast, no activation of NF-
κB and/or AP-1 was seen for the tested AON’s compared to saline treated RAW-blue cells, except that
AON80.5.1 induced a minor increase in SEAP at a final concentration of 1 µM, which might suggest
activation of NF-κB and/or AP-1. Detected values were compared to saline using a One-Way ANOVA
with Holm-Sidak test for multiple comparisons for SEAP (OD) measurements.
Immunotoxicity of AON’s during 24hrs of in vitro stimulation was also tested using RAW-Blue cells,
looking for an increase in resorufin levels (which could be explained by increased proliferation leading to
an increased cell number and/or by accelerated cell metabolism due to PPR activation). No effect on cell
viability was observed after stimulation with any of the AON’s (Figure 7). Only the positive control CpG-
DNA gave markedly elevated levels of synthesized resorufin (but the absence of an effect with LPS and
R848 could be due to the use of old batches). Detected values were compared to saline using a One-
Way ANOVA with Holm-Sidak test for multiple comparisons for resorufin measurements.
The functionality, e.g. protein stability and anchor fibril formation, of collagen VII without the exon 80
can be addressed using several in vitro methods described in literature:
1. Protein analysis, both size and correct assembly of the α1-collagen chains, using western
blotting (Titeux et al. 2010). Of note, due to the small size of the skipped exon and the large
size of the wild type protein, the apparent difference in protein size may not be picked-up.
2. Thermal stability analysis of the collagen VII homotrimer, by using western blotting under
non-reduced conditions. Wild-type collagen VII is comprised of three α1-collagen a chains,
and has a Tm of 41°C (Mecklenbeck. 2002).
3. Cell migration analysis using colloidal gold or scratch Radius™ 24-Well Cell Migration Assay.
Compare the motility of fibroblasts and/or keratinocytes that express wild-type collagen VII
vs the truncated protein without exon 80 (Chen et al. 2002). Or compare motility of
keratinocytes in presence of treated vs non-treated mutant human fibroblast cell culture
medium.
4. Cell adhesion to various extracellular matrix components can be assessed, e.g. to collagen
IV, laminin-332, laminin-1 or fibronectin (Chen et al. 2002).
The inventors of the present invention postulate that the AONs shown to perform the best in terms of
preventing, or at least reducing, exon 80 inclusion into the mammalian (preferably human) COL7A1
mRNA will provide satisfactory results in terms of collagen VII functionality, as can be readily assessed
using the above methods from the prior art.
It will be understood that the invention is described above by way of example only and modifications
may be made whilst remaining within the scope and spirit of the invention.
Reference list
Chen et al. Nat Genet. 2002, Dec; 32(4): 670-5. Restoration of type VII collagen expression and function
in dystrophic epidermolysis bullosa.
Chiorini JA, Kim F, Yang L and Koting RM. J. of Virology 1999 Feb;73(2):1309-19. Cloning and
characterization of adeno-associated virus type 5.
Dorn A and Kippenberger. Mol Ther 2008. Feb;10(1):10-20. Clinical application of CpG-, non-CpG-, and
antisense oligodeoxynucleotides as immunomodulators. Curr opin.
Egholm M et al. Nature 1993. Oct 7; 365(6446): 566-8.PNA hybridizes to complementary
oligonucleotides obeying the Watson-Crick hydrogen-bonding rules.
Fine et al., J. Am Acad Dermatol.2014. Jun;70(6):1103-26. Inherited epidermolysis bullosa: Updated
recommendations on diagnosis and classification.
Goto M et al. J. Invest Dermatol. 2006. Dec;126(12):2614-20. Targeted Skipping of a Single Exon
Harboring a Premature Termination Codon Mutation: Implications and Potential for Gene Correction
Therapy for Selective Dystrophic Epidermolysis Bullosa Patients.
Govindaraju T and Kumar VA. Chem Commun (Camb) 2005. Jan 28;(4):495-7. Backbone-extended
pyrrolidine peptide nucleic acids (bepPNA): design, synthesis and DNA/RNA binding studies.
Keswani SG et al Wound Repair Regen. 2012. Jul-Aug;20(4):592-600.Pseudotyped adeno-associated viral
vector tropism and transduction efficiencies in murine wound healing.
Mecklenbeck Hum Gen Ther. 2002 Sep 1;13(13):1655-62. A microinjected COL7A1-PAC vector restores
synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line.
Nielsen PE et al. Science 1991. Dec 6;254(5037):1497-500. Sequence-selective recognition of DNA by
strand displacement with a thymine-substituted polyamide.
Titeux M. et al. Mol. Ther. 2010. Aug;18(8):1509-18SIN retroviral vectors expressing COL7A1 under
human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.
Claims (14)
1. An antisense oligonucleotide (AON) capable of preventing or reducing exon 80 inclusion into a human COL7A1 mRNA when said mRNA is produced by splicing from a pre-mRNA in a cell, wherein the AON consists of a nucleotide sequence selected from the group consisting of SEQ ID Nos: 8, 25, 26, 31 and 32.
2. An AON according to claim 1, wherein the AON comprises a region of complementarity with exon 80 wherein said region of complementarity is at most 20 nucleotides in length.
3. An AON according to claim 1 or 2, wherein the AON comprises a region of complementarity with exon 80 wherein said region of complementarity is 11, 12, 13, 14, 15, 16 or 17 nucleotides.
4. An AON according to any one of claims 1 to 3, wherein the AON is less than 24 nucleotides in length.
5. An AON according to any one of claims 1 to 4, wherein the AON comprises 20, 21, 22, or 23 nucleotides.
6. An AON according to any one of claims 1 to 5, wherein the AON is an oligoribonucleotide.
7. An AON according to any one of claims 1 to 6, wherein the internucleosidic linkages are chemically modified.
8. An AON according to any one of claims 1 to 7, wherein the internucleosidic linkages are phosphorothioate-linkages.
9. An AON according to any one of claims 1 to 8, wherein the sugar moieties of the AON are lower 2’- O-alkyl, substituted sugar moieties.
10. An AON according to any one of claims 1 to 9, wherein the sugar moieties of the AON are 2’-O- methyl substituted sugar moieties.
11. A composition comprising an oligonucleotide according to any one of claims 1 to 10, and one or more of a carrier, excipient, stabilizer, transfection agent, diluent, gelling agent or buffer.
12. A composition according to claim 11, which is a pharmaceutical composition for use in human therapy.
13. An in vitro method for preventing or reducing exon 80 inclusion into a human COL7A1 mRNA when said mRNA is produced by splicing from an RNA transcript in a human, cell; said method comprising the steps of providing to a cell, an oligonucleotide according to any one of claims 1 to 10, or a composition according to claim 11 or 12, under conditions conducive to uptake of such oligonucleotide by such cell, and allowing splicing to take place.
14. Use of an oligonucleotide according to any one of claims 1 to 10 in the manufacture of a medicament for treating an individual having dystrophic epidermolysis bullosa.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1508733.1 | 2015-05-21 | ||
GBGB1508733.1A GB201508733D0 (en) | 2015-05-21 | 2015-05-21 | Antisense oligonucleotides |
GBGB1516505.3A GB201516505D0 (en) | 2015-09-17 | 2015-09-17 | Antisense oligonucleotides |
GB1516505.3 | 2015-09-17 | ||
PCT/EP2016/061495 WO2016185041A1 (en) | 2015-05-21 | 2016-05-20 | Antisense oligonucleotides to treat dystrophic epidermolysis bullosa |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ737592A NZ737592A (en) | 2021-08-27 |
NZ737592B2 true NZ737592B2 (en) | 2021-11-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11920132B2 (en) | Oligonucleotide therapy for Leber congenital amaurosis | |
US11352626B2 (en) | Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy | |
KR20190051020A (en) | Antisense oligonucleotides for treating eye diseases | |
JP7188804B2 (en) | Antisense oligonucleotides for treating dystrophic epidermolysis bullosa | |
WO2018189376A1 (en) | Antisense oligonucleotides for the treatment of stargardt disease | |
US20220127610A1 (en) | Oligonucleotides for use in the treatment of dystrophic epidermolysis bullosa | |
NZ737592B2 (en) | Antisense oligonucleotides to treat dystrophic epidermolysis bullosa | |
NZ736083B2 (en) | Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy |